Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The optimal management of patients exhibiting a partial virologic response (PVR) to entecavir (ETV) has not been determined . The aim of this study was to determine the long-term efficacy of prolonged ETV monotherapy in treatment-naïve chronic hepatitis B (CHB) patients exhibiting a PVR to ETV therapy. Methods: This study included 364 treatment-naïve CHB patients treated with ETV for ≥48 weeks and who received continuous ETV monotherapy for ≥96 weeks. PVR was defined as a decrease in serum hepatitis B virus (HBV) DNA of more than 2 log10 IU/mL from baseline but with detectable HBV DNA by real-time PCR assay at week 48. Results: Fifty-two of the 364 patients (14.3%) showed a PVR. Among them, 41 patients received continuous ETV monotherapy for ≥96 weeks (median duration 144 weeks, range 96–312 weeks), and 40 of these patients (95%) achieved a virologic response (VR, HBV DNA <20 IU/mL) during prolonged ETV monotherapy (median duration 78 weeks, range 60–288 weeks). The cumulative probabilities of a VR at weeks 96, 144, and 192 from treatment initiation were 78.0%, 92.7%, and 95.1%, respectively. The VR rate was 97.2% (35/36) in HBeAg-positive patients and 100% (5/5) in HBeAg-negative patients. In multivariate analysis, HBeAg positivity (odds ratio [OR], 9.231; 95% confidence interval [CI], 1.03–82.91; P=0.047) and a high baseline HBV DNA level (OR, 0.170; 95% CI, 0.08–0.37; P=0.000) were independently associated with a delayed virologic response. No patient developed genotypic resistance to ETV during follow-up. Conclusions: Long-term ETV monotherapy is effective for achieving a VR in treatment-naïve CHB patients exhibiting a PVR to ETV. HBeAg positivity and high baseline HBV DNA level were independently associated with a delayed virologic response. (Clin Mol Hepatol 2015;21:24-31)
Abstract
Background/Aims: The optimal management of patients exhibiting a partial virologic response (PVR) to entecavir (ETV) has not been determined . The aim of this study was to determine the long-term efficacy of prolonged ETV monotherapy in treatment-naïve chronic hepatitis B (CHB) patients exhibiting a PVR to ETV therapy. Methods: This study included 364 treatment-naïve CHB patients treated with ETV for ≥48 weeks and who received continuous ETV monotherapy for ≥96 weeks. PVR was defined as a decrease in serum hepatitis B virus (HBV) DNA of more than 2 log10 IU/mL from baseline but with detectable HBV DNA by real-time PCR assay at week 48. Results: Fifty-two of the 364 patients (14.3%) showed a PVR. Among them, 41 patients received continuous ETV monotherapy for ≥96 weeks (median duration 144 weeks, range 96–312 weeks), and 40 of these patients (95%) achieved a virologic response (VR, HBV DNA <20 IU/mL) during prolonged ETV monotherapy (median duration 78 weeks, range 60–288 weeks). The cumulative probabilities of a VR at weeks 96, 144, and 192 from treatment initiation were 78.0%, 92.7%, and 95.1%, respectively. The VR rate was 97.2% (35/36) in HBeAg-positive patients and 100% (5/5) in HBeAg-negative patients. In multivariate analysis, HBeAg positivity (odds ratio [OR], 9.231; 95% confidence interval [CI], 1.03–82.91; P=0.047) and a high baseline HBV DNA level (OR, 0.170; 95% CI, 0.08–0.37; P=0.000) were independently associated with a delayed virologic response. No patient developed genotypic resistance to ETV during follow-up. Conclusions: Long-term ETV monotherapy is effective for achieving a VR in treatment-naïve CHB patients exhibiting a PVR to ETV. HBeAg positivity and high baseline HBV DNA level were independently associated with a delayed virologic response. (Clin Mol Hepatol 2015;21:24-31)
참고문헌 (37)
- European Association for the Study Of The Liver, "EASL Clinical Practice Guidelines: Management of chronic hepatitis B", J Hepatol, 57, pp.167~185 (2012)
- Korean Association for the Study of the Liver, "KASL Clinical Practice Guidelines : Management of chronic hepatitis B", Clin Mol Hepatol, 18, pp.109~162 (2012)
- Raimondo G, "Statements from the Taormina expert meeting on occult hepatitis B virus infection", J Hepatol, 49, pp.652~657 (2008)
- Brechot C, "State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and-negative liver diseases", Proc Natl Acad Sci USA, 78, pp.3906~3910 (1981)
- Brechot C, "Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface ntigen: clinically significant or purely ‘‘occult’’?", Hepatology, 34, pp.194~203 (2001)
- Liaw YF, "Hepatitis B virus replication and liver disease progression : the impact of antiviral therapy", Antivir Ther, 11, pp.669~679 (2006)
- Mommeja-Marin H, "Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection : analysis and review of the literature", Hepatology, 37, pp.1309~1319 (2003)
- Yuan HJ, "The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B", J Viral Hepat, 12, pp.373~379 (2005)
- Liaw Y-F, "Asian-Pacific consensus statement on the management of chronic hepatitis B : a 2008 update", Hepatol Int, 2, pp.263~283 (2008)
- Lok ASF, "Chronic hepatitis B : update 2009", Hepatology, 50, pp.661~662 (2009)
- Ko SY, "Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy", Scand J Gastroenterol, 47, pp.1362~1367 (2012)
- Lai CL, "Telbivudine versus lamivudine in patients with chronic hepatitis B", N Engl J Med, 357, pp.2576~2588 (2007)
- Zoutendijk R, "Entecavir treatment for chronic hepatitis B : adaptation is not needed for the majority of naive patients with a partial virological response", Hepatology, 54, pp.443~451 (2011)
- Lampertico P, "Partial virological response to nucleos(t)ide analogues in naive patients with chronic hepatitis B : From guidelines to field practice", J Hepatol, 50, pp.644~647 (2009)
- Ono A, "Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients", J Hepatol, 57, pp.508~514 (2012)
- Yuen MF, "Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety", Am J Gastroenterol, 106, pp.1264~1271 (2011)
- 권대훈, "Continuous Long-Term Entecavir Therapy in Naïve Chronic Hepatitis B Patients Showing Partial Virologic Response", Gut and Liver, 7(6), pp.712~718 (2013), 거트앤리버 발행위원회
- Hong SP, "Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments", J Hepatol, 40, pp.837~844 (2004)
- Han KH, "Comparison of multiplex restric¬tion fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B", Antivir Ther, 16, pp.77~87 (2011)
- Hadziyannis SJ, "Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years", Gastroenterology, 131, pp.1743~1751 (2006)
- Yuen MF, "Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy", Hepatology, 34, pp.785~791 (2001)
- Zeuzem S, "Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B", J Hepatol, 51, pp.11~20 (2009)
- Liaw YF, "2-Year GLOBE trial results : telbivudine is superior to lamivudine in patients with chronic hepatitis B", Gastroenterology, 136, pp.486~495 (2009)
- Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
- Chang TT, "Entecavir treatment for up to 5 years in patients with hepatitis B e antigenpositive chronic hepatitis B", Hepatology, 51, pp.422~430 (2010)
- Lai CL, "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 354, pp.1011~1020 (2006)
- Shouval D, "Three years of entecavir (ETV) re-treatment of HBeAg(-) ETV patients who previously discontinued ETV treatment: results from study ETV-901", Hepatology, 48, pp.722A~ (2008)
- Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
- Lampertico P, "Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine", Hepatology, 42, pp.1414~1419 (2005)
- Kim do Y, "Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B", Intervirology, 51, pp.293~298 (2008)
- Lee JM, "Longterm adefovir dipivoxil monotherapy for up to 5 years in lamivudineresistant chronic hepatitis B", Antivir Ther, 15, pp.235~241 (2010)
- Lee JM, "Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B : adefovir versus entecavir", Antivir Ther, 14, pp.705~712 (2009)
- Kim H, "Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization", Antivir Ther, 10, pp.441~449 (2005)
- Han KH, "Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B", Antivir Ther, 16, pp.77~87 (2011)
- Papatheodoridis GV, "Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine", Hepatology, 42, pp.121~129 (2005)
- Yang YJ, "Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy", Hepatology, 59, pp.1303~1310 (2014)
- Chen CH, "Antiviral effect of entecavir in nucleos(t)ide analogue-na€ıve and nucleos(t)ide analogueexperienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy", Journal of Viral Hepatitis, 21, pp.e55~e64 (2014)